Reversal effect of tyroservatide (YSV) tripeptide on multi-drug resistance in resistant human hepatocellular carcinoma cell line BEL-7402/5-FU

Cancer Letters

Volumn 269, Issue 1, 2008, Pages 101-110

  Shi, Lin xi ^a,b   Ma, Rui ^a   Lu, Rong ^a,c   Xu, Qiong ^a   Zhu, Zhi feng ^a   Wang, Li ^a   Zhou, Chun lei ^a   Li, Xiao lei ^a   Zhang, Hua li ^a   Yao, Zhi ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b KUNMING MEDICAL UNIVERSITY   (China)

^c Shenzhen Kangzhe Pharmaceutical Co Ltd   (China)

Author keywords

Hepatocellular carcinoma; Modulator; Multi drug resistance; Tyroservatide

Indexed keywords

DOXORUBICIN; FLUOROURACIL; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; RHODAMINE 123; TRIPEPTIDE DERIVATIVE; TYROSERVATIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL LEVEL; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; LIVER NEOPLASMS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; OLIGOPEPTIDES; P-GLYCOPROTEIN; RHODAMINE 123; RNA, MESSENGER; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 49349114710     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.04.033     Document Type: Article

References (34)

1. Tang Z.Y. Small hepatocellular carcinoma: current status and prospects. HBPD INT 1 (2002) 349-353
2. Gottesman M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 53 (2002) 615-627
3. Jia J., Lu R., Fu Z., Qiu S., Shi L.X., Jian X., Liu J.Y., Li H.Q., Che X.C., and Yao Z. Tyroservatide inhibits the growth of human hepatocarcinoma in nude mice. Zhonghua Zhong Liu Za Zhi 28 (2006) 426-428
4. Jia J., Lu R., Qiu S., Li H., Che X., Zhao P., Jin M., Yang H., Lin G., and Yao Z. Preliminary investigation of the inhibitory effects of the tyroservaltide (YSV) tripeptide on human hepatocarcinoma BEL-7402. Cancer Biol. Ther. 4 (2005) 993-997
5. Cory A.H., Owen T.C., Barltrop J.A., and Cory J.G. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun. 3 (1991) 207-212
6. Mistry P., Stewart A.J., Dangerfield W., Okiji S., Liddle C., Bootle D., Plumb J.A., Templeton D., and Charlton P. In vitro and in vivo reversal of P-glycoprotein-mediated multi-drug resistance by a novel potent modulator, XR9576. Cancer Res. 61 (2001) 749-758
7. Jin J., Wang F.P., Wei H., and Liu G. Reversal of multi-drug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine. Cancer Chemother. Pharmacol. 55 (2005) 179-188
8. Gao F.L., Wang F., Wu J.L., Le X.P., and Zhang Q.X. Screening effective sequences of small interfering RNAs targeting MDR1 gene in human gastric cancer SGC7901/VCR cells. Zhonghua Zhong Liu Za Zhi 28 (2006) 178-182
9. Hong L., Piao Y., Han Y., Wang J., Zhang X., Du Y., Cao S., Qiao T., Chen Z., and Fan D. Zinc ribbon domain-containing 1 (ZNRD1) mediates multi-drug resistance of leukemia cells through regulation of P-glycoprotein and Bcl-2. Mol. Cancer Ther. 4 (2005) 1936-1942
10. Xu D., Lu Q., and Hu X. Down-regulation of P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by honokiol. Cancer Lett. 243 (2006) 274-280
11. Dussault A.A., and Pouliot M. Rapid and simple comparison of messenger RNA levels using real-time PCR. Biol. Proced. Online 8 (2006) 1-10
12. Wang X., Kong L., Zhao J., and Yang P. Arsenic trioxide in the mechanism of drug resistance reversal in MCF-7/ADM cell line of human breast cancer. Zhonghua Zhong Liu Za Zhi 24 (2002) 339-343
13. Narasaki F., Oka M., Fukuda M., Nakano R., Ikeda K., Takatani H., Terashi K., Soda H., Yano O., Nakamura T., Doyle L.A., Tsuruo T., and Kohno S. A novel quinoline derivative, MS-209, overcomes drug resistance of human lung cancer cells expressing the multi-drug resistance-associated protein (MRP) gene. Cancer Chemother. Pharmacol. 40 (1997) 425-432
14. Brooks T.A., Minderman H., O'Loughlin K.L., Pera P., Ojima I., Baer M.R., and Bernacki R.J. Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multi-drug resistance protein, and breast cancer resistance protein. Mol. Cancer Ther. 2 (2003) 1195-1205
15. Chen L.M., Liang Y.J., Ruan J.W., Ding Y., Wang X.W., Shi Z., Gu L.Q., Yang X.P., and Fu L.W. Reversal of P-gp mediated multi-drug resistance in-vitro and in-vivo by FG020318. J. Pharm. Pharmacol. 56 (2004) 1061-1066
16. Minderman H., O'Loughlin K.L., Pendyala L., and Baer M.R. VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin. Cancer Res. 10 (2004) 1826-1834
17. Limtrakul P., Khantamat O., and Pintha K. Inhibition of P-glycoprotein activity and reversal of cancer multidrug resistance by Momordica charantia extract. Cancer Chemother. Pharmacol. 54 (2004) 525-530
18. Clark F.S., Parkinson T., Hitchcock C.A., and Gow N.A. Correlation between rhodamine 123 accumulation and azole sensitivity in Candida species: possible role for drug efflux in drug resistance. Antimicrob. Agents Chemother. 40 (1996) 419-425
19. Anuchapreeda S., Leechanachai P., Smith M.M., Ambudkar S.V., and Limtrakul P.N. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem. Pharmacol. 64 (2002) 573-582
20. Tan B., Piwnica-Worms D., and Ratner L. Multidrug resistance transporters and modulation. Curr. Opin. Oncol. 12 (2000) 450-458
21. Sarkadi B., Homolya L., Szakács G., and Váradi A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol. Rev. 86 (2006) 1179-1236
22. Pérez-Tomás R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr. Med. Chem. 13 (2006) 1859-1876
23. Newman M.J., Rodarte J.C., Benbatoul K.D., Romano S.J., Zhang C., Krane S., Moran E.J., Uyeda R.T., Dixon R., Guns E.S., and Mayer L.D. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res. 60 (2000) 2964-2972
24. Green L.J., Marder P., and Slapak C.A. Modulation by LY335979 of P-glycoprotein function in multidrug-resistant cell lines and human natural killer cells. Biochem. Pharmacol. 61 (2001) 1393-1399
25. Gottesman M.M., Fojo T., and Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2 (2002) 48-58
26. Loo T.W., Bartlett M.C., and Clarke D.M. Substrate-induced conformational changes in the transmembrane segments of human P-glycoprotein. Direct evidence for the substrate-induced fit mechanism for drug binding. J. Biol. Chem. 278 (2003) 13603-13606
27. Deeley R.G., Westlake C., and Cole S.P. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol. Rev. 86 (2006) 849-899
28. Baritaki S., Apostolakis S., Kanellou P., Dimanche-Boitrel M.T., Spandidos D.A., and Bonavida B. Reversal of tumor resistance to apoptotic stimuli by alteration of membrane fluidity: therapeutic implications. Adv. Cancer Res. 98 (2007) 149-190
29. Bouhamyia L., Chantot-Bastaraud S., Zaidi S., Roynard P., Prengel C., Bernaudin J.F., and Fleury-Feith J. Immunolocalization and cell expression of lung resistance-related protein (LRP) in normal and tumoral human respiratory cells. J. Histochem. Cytochem. 55 (2007) 773-782
30. Steiner E., Holzmann K., Elbling L., Micksche M., and Berger W. Cellular functions of vaults and their involvement in multidrug resistance. Curr. Drug Targets 7 (2006) 923-934
31. Jin J., Huang M., Wei H.L., and Liu G.T. Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel(7402). World J. Gastroenterol. 8 (2002) 1029-1034
32. Kirihara Y., Yamamoto W., Toge T., and Nishiyama M. Dihydropyrimidine dehydrogenase, multidrug resistance-associated protein, and thymidylate synthase gene expression levels can predict 5-fluorouracil resistance in human gastrointestinal cancer cells. Int. J. Oncol. 14 (1999) 551-556
33. Teodori E., Dei S., Martelli C., Scapecchi S., and Gualtieri F. The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR). Curr. Drug Targets 7 (2006) 893-909
34. Rajagopal A., and Simon S.M. Subcellular localization and activity of multidrug resistance proteins. Mol. Biol. Cell 14 (2003) 3389-3399